PMID: 6103386May 10, 1980Paper

Use of modified subcutaneous right-atrial catheter for venous access in leukaemic patients

Lancet
H A BlacklockJ C Wade

Abstract

A large-diameter indwelling subcutaneous right-atrial catheter was inserted in 25 patients with haematological malignancies and neutropenia to provide ready access to the venous system for all infusions and blood aspirations. The median duration of catheter placement was 70 days. In 23 patients (92%) the catheter was used successfully until remission or death. Catheter-related exit-site infectons, generally mild, occurred in 14 patients (56%), Staphylococcus epidermidis being the predominant organism cultured. Septicaemia occurred in 11 neutropenic patients (44%). In 2 patients the same organism was grown from blood and exit site. The use of this catheter greatly facilitates patient care and support, minimises discomfort, and is associated with an acceptable rate of complications.

References

Oct 1, 1974·Annals of Internal Medicine·G H GinsbergH Kaupp

❮ Previous
Next ❯

Citations

Aug 1, 1983·Archives of Disease in Childhood·M StockwellK Pai
Feb 1, 1985·Archives of Disease in Childhood·P J DarbyshireD C Speller
Jun 8, 1985·British Medical Journal·H GilliesC J Rudge
Dec 7, 1985·British Medical Journal·A E YoungM Lambert
Aug 1, 1981·The Australian and New Zealand Journal of Surgery·P A BraithwaiteR M Lowenthal
Dec 1, 1985·The Australian and New Zealand Journal of Surgery·J P FletcherM McGurgan
Apr 1, 1984·American Journal of Surgery·A BotheJ J Lokich
Jun 1, 1990·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·T RannemS Jarnum
Sep 1, 1989·European Journal of Cancer & Clinical Oncology·J VerhoefA W Dekker
Mar 1, 1992·JPEN. Journal of Parenteral and Enteral Nutrition·W D Haire, R P Lieberman
Jan 1, 1995·JPEN. Journal of Parenteral and Enteral Nutrition·L C StephensG D Kotulak
Feb 1, 1988·Clinical Pediatrics·J CasseyA J Martin
Apr 1, 1987·Cancer·M P KrogN O Simonsson
Dec 1, 1984·Cancer·S MentzerG Steele
Jun 8, 1985·British Medical Journal·M Z SiodlakC L Wengraf
Apr 1, 1986·Australian and New Zealand Journal of Medicine·M P HarveyH Kronenberg
Jun 1, 1987·Australian and New Zealand Journal of Medicine·H LuntP J Dady
Mar 1, 1985·Acta Radiologica. Oncology·H Starkhammar, M Bengtsson
Feb 1, 1989·The Journal of Urology·J C SpringerH G Mesrobian
Jan 1, 1987·Pediatric Hematology and Oncology·D L BectonT R Kinney
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L NouwenS de Marie
Oct 1, 1990·Journal of Surgical Oncology·C O FreytesK L Smith
May 1, 1989·Journal of Surgical Oncology·P HallJ Swedenborg
Oct 1, 1984·Drug Intelligence & Clinical Pharmacy·G S Umstead
Apr 1, 1988·Journal of Surgical Oncology·E S KondiJ A Barriola
Jan 7, 1984·The Medical Journal of Australia·R A Bowman, M Buck

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.